Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence is not a edictive factor for response to interferon-alpha therapy and development of patocellular carcinoma.
10.3346/jkms.2000.15.1.53
- Author:
Si Hyun BAE
1
;
Young Min PARK
;
Duck Gi YOO
;
Jong Young CHOI
;
Byung Hun BYUN
;
Jin Mo YANG
;
Chang Don LEE
;
Sang Bok CHA
;
Doo Ho PARK
;
Boo Sung KIM
Author Information
1. Department of Internal Medicine, Kangnam St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Hepatitis C Chronic;
Genotype;
Viral Nonstructural Proteins;
Interferon-Alpha;
Carcinoma;
hepatocellular
- MeSH:
Adult;
Aged;
Amino Acid Sequence;
Antiviral Agents/therapeutic use*;
Base Sequence;
Carcinoma, Hepatocellular/virology*;
Carcinoma, Hepatocellular/blood;
Codon;
Female;
Genotype;
Hepatitis C, Chronic/virology*;
Hepatitis C, Chronic/drug therapy*;
Hepatitis C, Chronic/blood;
Hepatitis C-Like Viruses/isolation & purification;
Hepatitis C-Like Viruses/genetics*;
Hepatitis C-Like Viruses/classification;
Human;
Interferon-alpha/therapeutic use*;
Liver Neoplasms/virology*;
Liver Neoplasms/blood;
Male;
Middle Age;
Molecular Sequence Data;
Mutation*;
Prognosis;
Reverse Transcriptase Polymerase Chain Reaction
- From:Journal of Korean Medical Science
2000;15(1):53-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
Genetic changes between codons 2209 and 2248 of NS5A of genotype 1b hepatitis C virus (HCV-1b) have been reported to be associated with the sensitivity to interferon-alpha (IFN-alpha). The present study was performed to analyze such relationship in Korean patients with chronic hepatitis C and HCV-1b (n=19), including 12 chronic hepatitis C patients treated with IFN-alpha, 3 chronic hepatitis C patients without treatment as controls, and 4 patients with hepatocellular carcinoma (HCC). Two serum samples, before and after the treatment, were analyzed for the mutations by reverse transcription-polymerase chain reaction, cloning and sequencing. The mutations were identified in 32% (6/19), including five intermediate type (1-3 mutations) and one mutant type (4 or more). In 12 patients treated with IFN-alpha, the number of amino acid substitutions in NS5A2209-2248 was not associated with outcome of the treatment.
